Company intelligence / Profile preview

Orchestra BioMed

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Orchestra BioMed has strong proof-of-concept clinical data for BackBeat CNT and Virtue SAB technologies, with pivotal trials planned for 2023+ addressing hypertension in cardiac pacemaker patients and vascular interventions; it is funded through 2026 by proceeds from merger and prior investment

Therapeutic areas: Cardiovascular
Modalities: DeviceMedical device technology (BackBeat CNT)Virtue SAB
Industry: Therapeutic Medical Devices

Partnerships

Medtronic (strategic collaborator and investor)

Beyond the preview

Go deeper on Orchestra BioMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orchestra BioMed.

Explore the full profile